Whereas the stimulating effect of IFN-III as an adjuvant in influenza vaccine is canceled if administered intraperitoneally or subcutaneously, implying that these non-mucosal sites do not express significant IFN-III-responsive cells to produce TSLP-dependent antibodies (35). Here, TSLP is linked to influenza.